Terms: = Gastric cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
41 results:
1. Myotubularin-related-protein-7 inhibits mutant (G12V) k-ras by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract] [Full Text] [Related]
2. Characteristic Mutational Damages in gastric and Colorectal Adenocarcinomas.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
[TBL] [Abstract] [Full Text] [Related]
3. Machine learning models predict the mTOR signal pathway-related signature in the gastric cancer involving 2063 samples of 7 centers.
Zhang H; Zhuo H; Hou J; Cai J
Aging (Albany NY); 2023 Jun; 15(13):6152-6162. PubMed ID: 37341987
[TBL] [Abstract] [Full Text] [Related]
4. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
5. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
6. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the hras-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract] [Full Text] [Related]
7. Study of the active ingredients and mechanism of Sparganii rhizoma in gastric cancer based on HPLC-Q-TOF-MS/MS and network pharmacology.
Lu X; Zheng Y; Wen F; Huang W; Chen X; Ruan S; Gu S; Hu Y; Teng Y; Shu P
Sci Rep; 2021 Jan; 11(1):1905. PubMed ID: 33479376
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor].
Mi RH; Dang HB; Chen L; Han YL; Wang MF; Zhang YL; Chen L; Li DB; Wei XD
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3323-3327. PubMed ID: 33202495
[No Abstract] [Full Text] [Related]
9. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
Athauda A; Nankivell M; Langley RE; Alderson D; Allum W; Grabsch HI; Starling N; Chau I; Cunningham D
Eur J Cancer; 2020 Sep; 137():45-56. PubMed ID: 32745964
[TBL] [Abstract] [Full Text] [Related]
10. Anti-tumor effects of phenolic alkaloids of menispermum dauricum on gastric cancer
Wu D; Du J; Zhang Y; Su Y; Zhang H
J Cancer Res Ther; 2018 Jun; 14(Supplement):S505-S511. PubMed ID: 29970715
[TBL] [Abstract] [Full Text] [Related]
11. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines.
Carino A; Graziosi L; D'Amore C; Cipriani S; Marchianò S; Marino E; Zampella A; Rende M; Mosci P; Distrutti E; Donini A; Fiorucci S
Oncotarget; 2016 Sep; 7(38):61021-61035. PubMed ID: 27409173
[TBL] [Abstract] [Full Text] [Related]
12. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
Nishida T; Blay JY; Hirota S; Kitagawa Y; Kang YK
Gastric Cancer; 2016 Jan; 19(1):3-14. PubMed ID: 26276366
[TBL] [Abstract] [Full Text] [Related]
13. Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells.
Li X; Xu L; Li H; Zhao L; Luo Y; Zhu Z; Liu Y; Qu X
Mol Med Rep; 2015 Jun; 11(6):4547-54. PubMed ID: 25625229
[TBL] [Abstract] [Full Text] [Related]
14. Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
Ohtsubo K; Ishikawa D; Nanjo S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Yasumoto K; Gabata T; Matsui O; Ikeda H; Takamatsu Y; Iwakami S; Yano S
JOP; 2013 Sep; 14(5):515-20. PubMed ID: 24018598
[TBL] [Abstract] [Full Text] [Related]
15. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.
Duffy MJ; Lamerz R; Haglund C; Nicolini A; Kalousová M; Holubec L; Sturgeon C
Int J Cancer; 2014 Jun; 134(11):2513-22. PubMed ID: 23852704
[TBL] [Abstract] [Full Text] [Related]
16. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Wu X; Zhang J; Zhen R; Lv J; Zheng L; Su X; Zhu G; Gavine PR; Xu S; Lu S; Hou J; Liu Y; Xu C; Tan Y; Xie L; Yin X; He D; Ji Q; Hou Y; Ge D
J Transl Med; 2012 Aug; 10():180. PubMed ID: 22935382
[TBL] [Abstract] [Full Text] [Related]
17. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo.
Kobunai T; Watanabe T; Fukusato T
Anticancer Res; 2011 Nov; 31(11):3691-6. PubMed ID: 22110188
[TBL] [Abstract] [Full Text] [Related]
18. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
[TBL] [Abstract] [Full Text] [Related]
19. [Standardization of evaluation for target molecule in cancer therapy].
Ochiai A
Gan To Kagaku Ryoho; 2011 May; 38(5):709-14. PubMed ID: 21566428
[TBL] [Abstract] [Full Text] [Related]
20. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers.
Shimoyama S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):729-39. PubMed ID: 21327931
[TBL] [Abstract] [Full Text] [Related]
[Next]
